Gastroenteropancreatic Neuroendocrine Carcinomas: The NET G3 Subcategory Is a Reality
- PMID: 28280252
- PMCID: PMC5344638
- DOI: 10.1634/theoncologist.2016-0359
Gastroenteropancreatic Neuroendocrine Carcinomas: The NET G3 Subcategory Is a Reality
Abstract
This letter comments on a published review on well‐differentiated grade 3 neuroendocrine tumors.
Comment in
-
In Reply.Oncologist. 2017 Mar;22(3):359-360. doi: 10.1634/theoncologist.2016-0393. Oncologist. 2017. PMID: 28280253 Free PMC article.
Comment on
-
Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.Oncologist. 2016 Oct;21(10):1191-1199. doi: 10.1634/theoncologist.2015-0476. Epub 2016 Jul 8. Oncologist. 2016. PMID: 27401895 Free PMC article. Review.
References
-
- Milione M, Maisonneuve P, Spada F et al. The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: Morphological differentiation and proliferation identify different prognostic categories. Neuroendocrinology 2017;104:85–93. - PubMed
-
- Panzuto FA, Rinzivillo MA, Spada FB et al. Everolimus in pancreatic neuroendocrine carcinomas G3. Poster presented at: ENETS 2016 Meeting, March 9–11, 2016; Barcelona, Spain. Poster L17.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
